Literature DB >> 30515907

The sterol regulatory element-binding protein 2 is dysregulated by tau alterations in Alzheimer disease.

Chunyu Wang1,2, Fanpeng Zhao2, Katie Shen2, Wenzhang Wang2, Sandra L Siedlak2, Hyoung-Gon Lee3, Clyde F Phelix3, George Perry3, Lu Shen4, Beisha Tang4, Riqiang Yan5, Xiongwei Zhu2.   

Abstract

Disturbed neuronal cholesterol homeostasis has been observed in Alzheimer disease (AD) and contributes to the pathogenesis of AD. As the master switch of cholesterol biosynthesis, the sterol regulatory element-binding protein 2 (SREBP-2) translocates to the nucleus after cleavage/activation, but its expression and activation have not been studied in AD which is the focus of the current study. We found both a significant decrease in the nuclear translocation of N-terminal SREBP-2 accompanied by a significant accumulation of C-terminal SREBP-2 in NFT-containing pyramidal neurons in AD. N-terminal- SREBP-2 is also found in dystrophic neurites around plaques in AD brain. Western blot confirmed a significantly reduced nuclear translocation of mature SREBP-2 (mSREBP-2) in AD brain. Interestingly, reduced nuclear mSREBP-2 was only found in animal models of tauopathies such as 3XTg AD mice and P301L Tau Tg mice but not in CRND8 APP transgenic mice, suggesting that tau alterations likely are involved in the changes of mSREBP-2 distribution and activation in AD. Altogether, our study demonstrated disturbed SREBP-2 signaling in AD and related models, and proved for the first time that tau alterations contribute to disturbed cholesterol homeostasis in AD likely through modulation of nuclear mSREBP-2 translocation.
© 2018 International Society of Neuropathology.

Entities:  

Keywords:  Alzheimer disease; SREBP-2; dystrophic neurite; nuclear translocation; tau protein; transcription activity

Mesh:

Substances:

Year:  2019        PMID: 30515907     DOI: 10.1111/bpa.12691

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  5 in total

Review 1.  Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.

Authors:  Fei Yin
Journal:  FEBS J       Date:  2022-01-07       Impact factor: 5.622

Review 2.  Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α.

Authors:  Francisco Sáez-Orellana; Jean-Noël Octave; Nathalie Pierrot
Journal:  Cells       Date:  2020-05-14       Impact factor: 6.600

3.  CREB1K292 and HINFPK330 as Putative Common Therapeutic Targets in Alzheimer's and Parkinson's Disease.

Authors:  Rohan Gupta; Pravir Kumar
Journal:  ACS Omega       Date:  2021-12-16

4.  Preventive Impact of Long-Term Ingestion of Chestnut Honey on Glucose Disorders and Neurodegeneration in Obese Mice.

Authors:  Simona Terzo; Pasquale Calvi; Domenico Nuzzo; Pasquale Picone; Giacoma Galizzi; Luca Caruana; Marta Di Carlo; Laura Lentini; Roberto Puleio; Flavia Mulè; Antonella Amato
Journal:  Nutrients       Date:  2022-02-11       Impact factor: 5.717

5.  Co-expression network analysis of human tau-transgenic mice reveals protein modules associated with tau-induced pathologies.

Authors:  Kazuya Tsumagari; Yoshiaki Sato; Aki Shimozawa; Hirofumi Aoyagi; Hideyuki Okano; Junro Kuromitsu
Journal:  iScience       Date:  2022-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.